Citigroup Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price

Zoetis (NYSE:ZTS) had its price objective dropped by investment analysts at Citigroup from $145.00 to $112.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective would indicate a potential upside of 45.02% from the stock’s previous close.

Other analysts have also recently issued research reports about the stock. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. UBS Group decreased their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Stifel Nicolaus set a $105.00 price objective on Zoetis in a report on Friday, May 8th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $134.75.

Zoetis Price Performance

NYSE ZTS traded up $3.01 during trading hours on Monday, reaching $77.23. The company’s stock had a trading volume of 4,952,899 shares, compared to its average volume of 5,050,831. The firm’s 50-day moving average price is $112.28 and its 200-day moving average price is $120.76. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis has a 1 year low of $72.38 and a 1 year high of $172.23. The company has a market capitalization of $32.38 billion, a price-to-earnings ratio of 12.83, a PEG ratio of 1.21 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts predict that Zoetis will post 6.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 11,650 shares of company stock worth $886,384 over the last quarter. Company insiders own 0.22% of the company’s stock.

Hedge Funds Weigh In On Zoetis

A number of institutional investors have recently modified their holdings of ZTS. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the fourth quarter valued at $25,000. Prosperity Bancshares Inc purchased a new position in Zoetis during the fourth quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis during the third quarter valued at approximately $31,000. Cassaday & Co Wealth Management LLC purchased a new position in Zoetis during the first quarter valued at approximately $28,000. Finally, Lodestone Wealth Management LLC purchased a new position in Zoetis in the fourth quarter valued at about $30,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.